ARAY

Accuray Incorporated
CAPPED RATING

Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise treatment solutions. Its products includes the CyberKnife Systems and the TomoTherapy Systems.

Accuray Incorporated (ARAY) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (F). The rating has held at C- for 4 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.0 / 5.0
C-
Value
C+
Factor Score 2.6 / 5.0
Growth
D+
Factor Score 1.7 / 5.0
Profitability
C+
Factor Score 2.6 / 5.0
Momentum
F
Factor Score 0.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -10.6
EV / EBITDA 24.1
Rev Growth YoY -7.9%
Gross Margin 28.0%
Price Return 3M -80.1%
Price Return 12M -94.3%
Catalyst Signal 0.00
Market Cap $7.7M
TTM Revenue $394.5M
Price / Sales 0.0
ROE -30.2%

Historical Factor Score Progression

Held C- for 4 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C+ (2.6) D+ (1.7) C+ (2.6) F (0.7) C+ (2.6) C- (2.0)
2026-11-10 B- (3.0) D (1.3) C (2.5) D- (1.0) C+ (2.6) C- (2.1)
2026-11-03 B- (3.0) D (1.3) C+ (2.5) D- (1.1) C+ (2.7) C- (2.1)
2026-10-27 B- (3.0) D (1.3) C (2.5) D- (0.9) C+ (2.6) C- (2.1)
2026-10-20 B- (3.0) D (1.3) C (2.5) D- (1.0) C+ (2.6) C- (2.1)
Page 1 of 8
…